<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations and diagnosis of acute interstitial nephritis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations and diagnosis of acute interstitial nephritis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations and diagnosis of acute interstitial nephritis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Manuel Praga, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gerald B Appel, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul M Palevsky, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric N Taylor, MD, MSc, FASN
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 04, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute interstitial nephritis (AIN) is a kidney lesion that typically causes a decline in kidney function and is characterized by an inflammatory infiltrate in the kidney interstitium [
         <a href="#rid1">
          1
         </a>
         ]. It is most often induced by drug therapy. AIN is also caused by autoimmune disorders or other systemic disease (eg, systemic lupus erythematosus [SLE], Sjögren's disease, sarcoidosis), a variety of infections remote to the kidney (eg,
         <em>
          Legionella
         </em>
         , leptospirosis, and streptococcal organisms), immunoglobulin G4 (IgG4) disease, and tubulointerstitial nephritis with uveitis (TINU) syndrome [
         <a href="#rid2">
          2-10
         </a>
         ].
        </p>
        <p>
         An overview of the clinical manifestations and diagnosis of AIN is presented in this topic review. The treatment of AIN is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7233.html" rel="external">
          "Treatment of acute interstitial nephritis"
         </a>
         .)
        </p>
        <p>
         Interstitial nephritis associated with SLE, sarcoidosis, the TINU syndrome, and Sjögren's disease is also discussed elsewhere.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3056.html" rel="external">
          "Lupus nephritis: Diagnosis and classification", section on 'Tubulointerstitial lesions'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7189.html" rel="external">
          "Tubulointerstitial nephritis and uveitis (TINU syndrome)"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7187.html" rel="external">
          "Kidney disease in primary Sjögren's disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7186.html" rel="external">
          "Kidney disease in sarcoidosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ETIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         In initial reports, the vast majority of cases of AIN resulted from exposure to beta-lactam antibiotics, particularly methicillin. However, drugs other than antibiotics, as well as infections and other underlying conditions, are also recognized as clinically significant causes.
        </p>
        <p>
         The distribution of causes of AIN has been reported as follows [
         <a href="#rid6">
          6,9,11-13
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drugs – 70 to 75 percent (with antibiotics responsible for approximately 30 to 50 percent of these cases)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systemic disease including sarcoidosis, Sjögren's disease, systemic lupus erythematosus (SLE), and others – 10 to 20 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infections – 4 to 10 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tubulointerstitial nephritis and uveitis (TINU) syndrome – less than 5 percent
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Virtually any drug can cause AIN, although only a few have been reported with any frequency. While there are single case reports of many drugs associated with AIN, we attribute cause to a previously unreported drug only when the study reports that AIN was confirmed by kidney biopsy and the patient was not concomitantly taking other drugs that can cause AIN. In many cases, a causal link with the drug is established by observing the onset of kidney function impairment after initiating the drug and its resolution after discontinuing the drug.
        </p>
        <p>
         On the other hand, it may be difficult to identify the culprit drug in some patients with biopsy-proven AIN who are taking multiple medications.
        </p>
        <p>
         AIN was particularly common with methicillin, occurring in up to 17 percent of patients who had been treated for more than 10 days [
         <a href="#rid5">
          5,14,15
         </a>
         ]. Methicillin is no longer manufactured.
        </p>
        <p>
         Other common drugs that cause AIN include [
         <a href="#rid2">
          2-4,13,15-29
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonsteroidal antiinflammatory agents (NSAIDs), including selective cyclooxygenase (COX)-2 inhibitors
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Penicillins and cephalosporins
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          Rifampin
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antimicrobial sulfonamides, including
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          Ciprofloxacin
         </a>
         and, perhaps to a lesser degree, other quinolones
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diuretics, including loop diuretics such as
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         and
         <a class="drug drug_general" data-topicid="9168" href="/z/d/drug information/9168.html" rel="external">
          bumetanide
         </a>
         , and thiazide-type diuretics
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">
          Cimetidine
         </a>
         (only rare cases have been described with other H-2 blockers such as
         <a class="drug drug_general" data-topicid="9853" href="/z/d/drug information/9853.html" rel="external">
          ranitidine
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">
          Allopurinol
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Proton pump inhibitors (PPIs) such as
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         and
         <a class="drug drug_general" data-topicid="9546" href="/z/d/drug information/9546.html" rel="external">
          lansoprazole
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         5-aminosalicylates (eg,
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anticancer drugs, such as immune checkpoint inhibitors (ICPi; such as
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         and
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         The development of drug-induced AIN is not dose-dependent, and a recurrence or exacerbation of AIN can occur with a second exposure to the same or a related drug [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         Several studies have shown an association between PPIs and AIN [
         <a href="#rid26">
          26-29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5.html" rel="external">
          "Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Kidney disease'
         </a>
         .)
        </p>
        <p>
         AIN can be a common complication among patients with inflammatory bowel diseases (IBD). In most patients with IBD, AIN has been attributed to treatment with 5-aminosalicylates [
         <a href="#rid31">
          31,32
         </a>
         ], although AIN has also been described in treatment-naïve patients [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         Different types of anticancer drugs can cause AIN [
         <a href="#rid34">
          34
         </a>
         ]. AKI has been reported in approximately 1 to 5 percent of patients receiving an ICPi (ie,
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">
          atezolizumab
         </a>
         ); AIN is the most common type of kidney pathology in such patients [
         <a href="#rid35">
          35-40
         </a>
         ]. In the largest observational study of ICPi-associated AKI, 93 percent of the patients biopsied had AIN [
         <a href="#rid39">
          39
         </a>
         ]. Median time of onset of AKI was 14 weeks (interquartile range 6 to 37 weeks). A lower baseline estimated glomerular filtration rate, concomitant use of PPIs, and combination therapy with different ICPis were independently associated with an increased risk of developing AKI. The vast majority of patients stopped the ICPi (97 percent) and were treated with glucocorticoids (86 percent). Complete or partial recovery was observed in 85 percent of patients. Re-introduction of the ICPi led to a recurrence of AKI in only 23 percent of patients. Additional details of kidney toxicity related to ICPis are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">
          "Toxicities associated with immune checkpoint inhibitors", section on 'Kidney'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple organisms have been associated with AIN including
         <em>
          Legionella
         </em>
         ,
         <em>
          Leptospira
         </em>
         , cytomegalovirus (CMV),
         <em>
          Streptococcus
         </em>
         ,
         <em>
          Mycobacterium
         </em>
         <em>
          tuberculosis
         </em>
         ,
         <em>
          Corynebacterium
         </em>
         <em>
          diphtheriae
         </em>
         , Epstein-Barr virus (EBV),
         <em>
          Yersinia
         </em>
         , polyomavirus,
         <em>
          Enterococcus
         </em>
         ,
         <em>
          Escherichia coli
         </em>
         , adenovirus,
         <em>
          Candida
         </em>
         , and others [
         <a href="#rid10">
          10,13,41-43
         </a>
         ]. A histologic variant of AIN that is characterized by granuloma formation has been associated with
         <em>
          Mycobacterium
         </em>
         , fungi (histoplasmosis, coccidioidomycosis), bacteria (
         <em>
          Brucella
         </em>
         ,
         <em>
          Chlamydia, Francisella
         </em>
         ), spirochetes (
         <em>
          Treponema
         </em>
         ), and parasites (
         <em>
          Leishmania
         </em>
         ,
         <em>
          Toxoplasma
         </em>
         ) [
         <a href="#rid44">
          44
         </a>
         ]. However, the most common etiology of granulomatous interstitial nephritis in westernized countries is medication-related disease [
         <a href="#rid45">
          45
         </a>
         ]. (See
         <a class="local">
          'Histology'
         </a>
         below.)
        </p>
        <p>
         Initial reports suggested that organisms such as
         <em>
          Legionella
         </em>
         ,
         <em>
          Leptospira
         </em>
         , CMV, and
         <em>
          Streptococcus
         </em>
         primarily invaded organs remote from the kidney and exerted an inflammatory response in the kidney without invading the kidney [
         <a href="#rid42">
          42,43
         </a>
         ]. However, more recent reports describe the identification of organism-specific antigens or DNA in kidney proximal tubule cells of patients with AIN [
         <a href="#rid41">
          41,46-48
         </a>
         ].
        </p>
        <p>
         Drug-induced AIN is also relatively common among HIV-infected patients, although infections and immunologic syndromes associated with HIV infection can also induce AIN [
         <a href="#rid49">
          49,50
         </a>
         ].
        </p>
        <p>
         AIN has rarely been reported in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus infection. With infection, the AIN may have been related to medications rather than the viral infection itself [
         <a href="#rid51">
          51,52
         </a>
         ]. AIN has also been reported after vaccination for SARS CoV-2 although proof of the vaccination as the etiologic stimulus is unproven [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Associated with systemic disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Numerous systemic disorders have been associated with AIN. These primarily include SLE, sarcoidosis, and Sjögren's disease. In a series of 133 patients with biopsy-proven AIN, of autoimmune etiologies, sarcoidosis was the most common [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7187.html" rel="external">
          "Kidney disease in primary Sjögren's disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7186.html" rel="external">
          "Kidney disease in sarcoidosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3056.html" rel="external">
          "Lupus nephritis: Diagnosis and classification", section on 'Tubulointerstitial lesions'
         </a>
         .)
        </p>
        <p>
         Patients with SLE and those with granulomatosis with polyangiitis often have interstitial nephritis accompanying the characteristic glomerular disease and may rarely present with AIN, even in the absence of glomerular disease.
        </p>
        <p>
         Less common causes of AIN include IgG4-related disease [
         <a href="#rid54">
          54,55
         </a>
         ] and hypocomplementemic tubulointerstitial nephritis [
         <a href="#rid56">
          56-58
         </a>
         ]. IgG4-related disease is a systemic disorder characterized by the infiltration of multiple organs by a lymphoplasmacytic infiltrate that is rich in IgG4-positive plasma cells, resulting in diverse clinical manifestations, including autoimmune pancreatitis, enlarged lacrimal and salivary glands and periorbital tissue, and tubulointerstitial nephritis [
         <a href="#rid54">
          54,59-65
         </a>
         ].
        </p>
        <p>
         A rare cause of AIN results from anti-tubular basement membrane (TBM) antibodies, leading to linear staining with immunoglobulin along the TBMs on immunofluorescence microscopy [
         <a href="#rid66">
          66-69
         </a>
         ]. This can occur in the presence or absence of concurrent anti-glomerular basement membrane antibodies [
         <a href="#rid66">
          66,67
         </a>
         ] and has been described in patients with membranous nephropathy [
         <a href="#rid69">
          69
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3050.html" rel="external">
          "Membranous nephropathy: Pathogenesis and etiology"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3108.html" rel="external">
          "Anti-GBM (Goodpasture) disease: Pathogenesis, clinical manifestations, and diagnosis", section on 'Kidney biopsy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4179513798">
         <span class="h2">
          Tubulointerstitial nephritis and uveitis (TINU) syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients with interstitial nephritis have the TINU syndrome. Patients present with interstitial nephritis and uveitis and occasionally with systemic findings including fever, weight loss, fatigue, malaise, anorexia, asthenia, abdominal and flank pain, arthralgias, myalgias, headache, polyuria, and/or nocturia. The TINU syndrome is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7189.html" rel="external">
          "Tubulointerstitial nephritis and uveitis (TINU syndrome)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1125126627">
         <span class="h2">
          Older patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         There may be differences in the distribution of underlying causes of AIN among older and younger patients. In one review, compared with patients ages 18 to 64 years (n = 88), patients older than 65 years (n = 45) were more likely to have drug-induced AIN (64 versus 87 percent) and less likely to have AIN related to autoimmune or systemic diseases (27 versus 7 percent) [
         <a href="#rid70">
          70
         </a>
         ]. There is no known biologic reason for this predilection, which is most likely related to polypharmacy in older individuals. The most common causative agents among older patients were penicillin and
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         .
        </p>
        <p>
         Two other forms of AIN have been described. One of them is characterized by a diffuse interstitial infiltration by immunoglobulin M (IgM)-positive plasma cells [
         <a href="#rid71">
          71
         </a>
         ]. The clinical findings included a mild-to-moderate kidney function impairment and a high prevalence of distal renal tubular acidosis, Fanconi syndrome, and antimitochondrial antibodies. Serum IgM levels were markedly elevated. Corticosteroid treatment led to kidney function improvement in this report. Another study reported 10 cases of tubulointerstitial nephritis caused by circulating antibodies reactive with megalin, an antigen present in the proximal tubule. The patients were older, presented with AKI and subnephrotic proteinuria, and responded poorly to corticosteroids [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2974465447">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         AIN is demonstrated in 1 to 3 percent of all kidney biopsies [
         <a href="#rid73">
          73,74
         </a>
         ]. When analysis is restricted to biopsies performed in the setting of acute kidney injury (AKI), the percentage rises to 13 to 27 percent [
         <a href="#rid74">
          74,75
         </a>
         ].
        </p>
        <p>
         Some studies suggest that the incidence of AIN is increasing, particularly among older subjects [
         <a href="#rid13">
          13,70,74
         </a>
         ]. The reasons for this change are complex and difficult to assess but may include an aging population base, increasing polypharmacy (including nonsteroidal antiinflammatory drugs [NSAIDs] and proton pump inhibitors [PPIs]) in older people, and an increasingly less restrictive policy of kidney biopsies in older patients with AKI. The true incidence of AIN may also be underestimated for the following reasons [
         <a href="#rid26">
          26
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A confirmatory kidney biopsy is often not done in older and frail patients; empirical treatment is often preferred.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The prevalence of AIN caused by PPIs, 5-aminosalicylates, and NSAIDs and often without obvious associated symptoms is increasing [
         <a href="#rid26">
          26
         </a>
         ]. Skin rash and eosinophilia are significantly less common with these drugs than in antibiotic-induced AIN. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H451377303">
         <span class="h2">
          Clinical manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         With AIN from any cause, patients may present with nonspecific signs and symptoms of acute kidney dysfunction. These may include the acute or subacute onset of nausea, vomiting, and malaise. However, many patients are asymptomatic [
         <a href="#rid10">
          10
         </a>
         ]. Patients may be oliguric or nonoliguric; in a retrospective study that included 60 cases of AIN (92 percent of which were drug induced, with the remainder idiopathic), oliguria was present among 51 percent [
         <a href="#rid11">
          11
         </a>
         ]. Gross hematuria occurs in approximately 5 percent of individuals [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         Patients usually do not have significant proteinuria, and nephrotic syndrome occurs in &lt;1 percent of patients with AIN [
         <a href="#rid11">
          11
         </a>
         ]. An exception occurs among patients who have nonsteroidal antiinflammatory drug (NSAID)-induced AIN, which may occur concurrently with NSAID-induced membranous nephropathy or minimal change disease. (See
         <a class="local">
          'NSAID-induced AIN and nephrotic syndrome'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/3050.html" rel="external">
          "Membranous nephropathy: Pathogenesis and etiology", section on 'Drugs'
         </a>
         .)
        </p>
        <p>
         Patients may present with symptoms related to the cause of the AIN. Classically, patients with drug-induced AIN were reported to have symptoms and/or signs of an allergic-type reaction, including rash, fever, and eosinophilia [
         <a href="#rid76">
          76
         </a>
         ]. However, in a more recent review of three series that totaled 128 patients with AIN (of whom 70 percent had drug-induced disease), these findings of a typical allergic response were relatively less common at presentation [
         <a href="#rid9">
          9
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rash – 15 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fever – 27 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eosinophilia – 23 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Triad of rash, fever, and eosinophilia – 10 percent
        </p>
        <p>
        </p>
        <p>
         A similar incidence of findings was reported in two retrospective series, which collected a total of 121 patients [
         <a href="#rid77">
          77,78
         </a>
         ]. Rash, fever, eosinophilia, and the triad were observed in 22, 36, 35, and 11 percent, respectively [
         <a href="#rid11">
          11
         </a>
         ]. Arthralgias were observed in 45 percent of the patients [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         Thus, the originally described classic triad is less commonly observed than initially reported. This is probably due to the absence of cases of methicillin-induced AIN and (perhaps) the increased inclusion of cases not directly resulting from an allergic response [
         <a href="#rid10">
          10
         </a>
         ]. In addition, some agents, such as NSAIDs and proton pump inhibitors (PPIs), are less commonly associated with fever, rash, and eosinophilia compared with other agents [
         <a href="#rid78">
          78,79
         </a>
         ].
        </p>
        <p>
         There is no typical range of time of onset for medication-induced AIN. The onset of drug-induced AIN following drug exposure may range from three to five days (as occurs with a second exposure to an offending drug), to as long as several weeks, to many months (as occurs following a first exposure to an offending drug) [
         <a href="#rid2">
          2,3
         </a>
         ]. However, the latent period from initial drug exposure may be as short as one day with
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         [
         <a href="#rid3">
          3
         </a>
         ] or as long as 18 months with an NSAID [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
         Patients who have AIN that is not related to a drug may have symptoms related to an associated infection or systemic condition such as systemic lupus erythematosus (SLE), sarcoidosis, the tubulointerstitial nephritis with uveitis (TINU) syndrome, and Sjögren's disease. (See
         <a class="medical medical_review" href="/z/d/html/7189.html" rel="external">
          "Tubulointerstitial nephritis and uveitis (TINU syndrome)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7187.html" rel="external">
          "Kidney disease in primary Sjögren's disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7186.html" rel="external">
          "Kidney disease in sarcoidosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3056.html" rel="external">
          "Lupus nephritis: Diagnosis and classification", section on 'Tubulointerstitial lesions'
         </a>
         .)
        </p>
        <p>
         Patients with immunoglobulin G4 (IgG4)-related interstitial nephritis may have extrarenal signs and symptoms. In a series of 23 patients, nonspecific symptoms such as fever, arthralgias, skin lesions, and edema were present in three, five, one, and two patients, respectively [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
         Overall, 96 percent of patients with IgG4-related AIN had extrarenal lesions, including sialadenitis in 19 (82 percent), lymphadenopathy in 10 (44 percent), autoimmune pancreatitis in 9 (39 percent), dacryoadenitis in 7 (30 percent), and lung lesions (interstitial pneumonia and nodular lesions) in 6 (26 percent) [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Laboratory and radiographic findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, patients with AIN present with some combination of the following laboratory findings, with some variation based upon the underlying cause [
         <a href="#rid2">
          2-4,9,77
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased plasma creatinine – Virtually all patients have a rise in the plasma creatinine concentration on presentation [
         <a href="#rid77">
          77,78
         </a>
         ]. If AIN is drug induced, the increase in creatinine is temporally related to administration of the offending drug. Acute kidney injury (AKI) may be severe; in two retrospective series, among 121 patients who presented with AIN, 40 percent required dialysis [
         <a href="#rid77">
          77,78
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eosinophilia and eosinophiluria – Although eosinophilia (defined by an absolute blood eosinophil count of ≥500 eosinophils/microL) is only found in 25 to 35 percent of AIN cases [
         <a href="#rid9">
          9,11,77,78
         </a>
         ], its finding in a patient with AKI with no other apparent cause should raise the suspicion of drug-induced AIN. Eosinophiluria, defined by eosinophils that account for more than 1 percent of urinary white cells by Hansel stain [
         <a href="#rid5">
          5,80
         </a>
         ], has been associated with AIN [
         <a href="#rid81">
          81
         </a>
         ]. However, urinary eosinophils are not useful in distinguishing AIN from other causes of AKI, and the absence of eosinophiluria does not exclude the possibility of AIN. The lack of clinical utility of eosinophils in diagnosing AIN was best shown in a retrospective study that correlated urinary eosinophils with biopsy-proven AIN [
         <a href="#rid82">
          82
         </a>
         ]. Five-hundred sixty-six patients had both a kidney biopsy and a test for urinary eosinophils performed for AKI. Among 179 patients who had a positive test for urinary eosinophils (defined as ≥1 percent of urinary white cells), only 28 had AIN on biopsy. Conversely, among 387 patients who had a negative test for eosinophils, 63 had biopsy-proven AIN. In this study, urinary eosinophils were found in multiple other kidney diseases, including acute tubular necrosis and crescentic and proliferative glomerulonephritis, and their presence did not alter the pretest probability of AIN on biopsy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some reports [
         <a href="#rid78">
          78,79
         </a>
         ], though not all [
         <a href="#rid82">
          82
         </a>
         ], have suggested that eosinophilia and eosinophiluria are less common in AIN induced by NSAIDs compared with other drugs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A characteristic urine sediment – The urine sediment usually reveals white cells, red cells, and white cell casts  (
         <a class="graphic graphic_picture graphicRef54319 graphicRef68147" href="/z/d/graphic/54319.html" rel="external">
          picture 1A-B
         </a>
         ). Red blood cell casts, which are typically seen in glomerulonephritis, have also been described in AIN, although this is rare [
         <a href="#rid83">
          83
         </a>
         ]. Some patients will, however, have no urinary sediment findings or isolated microhematuria and leukocyturia. The absence of urinary findings does not exclude a diagnosis of AIN.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A variable degree of proteinuria – Proteinuria can range from none or minimal to &gt;1 g/day. In two retrospective series that included a total of 121 patients, the mean and median protein excretions were 0.9±1.1 g/day (range 0 to 6 g/day) and 0.70 g/day (interquartile range 0.39 to 1.0 g/day), respectively [
         <a href="#rid77">
          77,78
         </a>
         ]. Older individuals may be more likely to have significant proteinuria [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Occasional patients will have nephrotic-range proteinuria [
         <a href="#rid2">
          2,3,11
         </a>
         ]. Concurrent nephrotic syndrome due to minimal change disease or membranous nephropathy can rarely be seen with NSAIDs and, in selected cases, induced by
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         , interferon, or
         <a class="drug drug_general" data-topicid="9853" href="/z/d/drug information/9853.html" rel="external">
          ranitidine
         </a>
         [
         <a href="#rid11">
          11,24,79,84,85
         </a>
         ]. In one study cited above, however, although proteinuria was significantly higher among NSAID-induced AIN as compared with other types of drug-induced AIN, nephrotic-range proteinuria was rare [
         <a href="#rid78">
          78
         </a>
         ]. In addition, although these and other drugs may induce heavy proteinuria [
         <a href="#rid14">
          14
         </a>
         ], an underlying disease (such as diabetic nephropathy or glomerulonephritis due to bacterial endocarditis) may be responsible for at least part of the proteinuria in some patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evidence of tubulointerstitial damage – Signs of tubulointerstitial damage, such as the Fanconi syndrome and renal tubular acidosis, may be present but rarely dominate the clinical picture [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High fractional sodium excretion – The fractional excretion of sodium (FENa) may be &gt;1 percent, which is in part indicative of tubular damage [
         <a href="#rid2">
          2
         </a>
         ]. Calculators for the FENa are available using either standard units (
         <a class="calc calc_professional" href="/z/d/html/13497.html" rel="external">
          calculator 1
         </a>
         ) or SI units (
         <a class="calc calc_professional" href="/z/d/html/13499.html" rel="external">
          calculator 2
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/7219.html" rel="external">
          "Fractional excretion of sodium, urea, and other molecules in acute kidney injury", section on 'Fractional excretion of sodium in acute kidney injury'
         </a>
         ). However, lower values may be seen, particularly in patients who are nonoliguric and have less severe kidney failure [
         <a href="#rid86">
          86,87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Radiographic findings – There are no radiographic findings that are diagnostic for AIN. Radiographic findings, including marked enlargement of kidneys with low-attenuation lesions, may be seen among patients with IgG4-related AIN [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H30834488">
         <span class="h3">
          IgG4-related disease and hypocomplementemic interstitial nephritis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to the above findings, patients with immunoglobulin G4 (IgG4)-related disease or hypocomplementemic interstitial nephritis usually have elevated serum total IgG and/or IgG4 levels or hypergammaglobulinemia and may have low serum complement concentrations [
         <a href="#rid63">
          63,88
         </a>
         ]. In one series of IgG4-related tubulointerstitial nephritis, among 23 patients, complement C3, C4, or both were reduced in 16 [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
         Microbiologic features unique to different culprit organisms are presented separately. (See appropriate topic reviews.)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         AIN should be suspected in a patient who presents with an elevated serum creatinine and a urinalysis that shows white cells, white cell casts, and, in some cases, eosinophiluria. Red blood cells and, rarely, red blood cell casts can be also observed [
         <a href="#rid89">
          89,90
         </a>
         ], although gross hematuria is distinctly unusual. Drug-induced AIN should be suspected when the onset of characteristic laboratory findings is temporally related to the initiation of a new drug, particularly one that has been previously reported to cause AIN. However, occasional patients have a bland sediment with few cells or casts [
         <a href="#rid18">
          18
         </a>
         ]. Thus, a relatively normal urinalysis should not exclude the diagnosis.
        </p>
        <p>
         A definitive diagnosis of AIN is made by kidney biopsy. It is often considered unnecessary to make a definitive diagnosis, such as among patients who have clearly documented onset of kidney failure after initiation of a common culprit drug and who improve immediately upon stopping the offending agent.
        </p>
        <p>
         We suggest a kidney biopsy for the following patients who are suspected of having AIN:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who have a characteristic urinalysis for AIN but are not being treated with a drug known to cause AIN.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who are being treated with a drug known to cause AIN but do not have a characteristic urinalysis. Some of the drugs that cause AIN can also produce other forms of acute kidney injury (AKI). As an example, nonsteroidal antiinflammatory drugs (NSAIDs) can exacerbate prekidney disease by inhibiting the production of vasodilator prostaglandins [
         <a href="#rid79">
          79
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7230.html" rel="external">
          "NSAIDs: Acute kidney injury"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who are being considered for treatment with glucocorticoids for AIN (usually drug induced). Among selected patients (such as those at high risk of complications of a biopsy or who do not wish to undergo a biopsy), glucocorticoids may be initiated without first obtaining a kidney biopsy. However, among patients who do not improve after the first five to seven days of empiric glucocorticoid therapy, those without contraindications should have a biopsy in order to exclude other diagnoses or severe interstitial fibrosis. (See
         <a class="medical medical_review" href="/z/d/html/3067.html" rel="external">
          "The kidney biopsy", section on 'Contraindications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7233.html" rel="external">
          "Treatment of acute interstitial nephritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with putative drug-related AIN who are not treated with glucocorticoids initially and do not have a recovery following cessation of drug therapy [
         <a href="#rid2">
          2,77
         </a>
         ]. We typically perform a kidney biopsy approximately two weeks after cessation of the offending drug if there has been no improvement in the kidney function over that time. However, clinicians wait a variable amount of time to allow for recovery before performing a biopsy. Some wait for three to four days, whereas others wait until the patient is approaching the need for kidney replacement therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who present with advanced kidney failure, providing the onset of kidney failure is known to be relatively recent (ie, within three months).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with any features (such as high-grade proteinuria) that cause the diagnosis of AIN to be uncertain.
        </p>
        <p>
        </p>
        <p>
         Patients who have a characteristic urinalysis for AIN but do not have an elevated creatinine may also be considered for biopsy, but such patients rarely come to medical attention since the urinalysis is usually only performed after the detection of an increased serum creatinine. Moreover, it is usually simpler and safer just to remove potential offending medications in such cases.
        </p>
        <p>
         The approach to the treatment of patients diagnosed with AIN, tubulointerstitial nephritis with uveitis (TINU), and kidney sarcoidosis is presented separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7233.html" rel="external">
          "Treatment of acute interstitial nephritis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7186.html" rel="external">
          "Kidney disease in sarcoidosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7189.html" rel="external">
          "Tubulointerstitial nephritis and uveitis (TINU syndrome)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H853752222">
         <span class="h2">
          Histology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The major histologic changes are interstitial edema and a marked interstitial infiltrate consisting primarily of T lymphocytes and monocytes  (
         <a class="graphic graphic_picture graphicRef66763 graphicRef64378 graphicRef78206 graphicRef55002 graphicRef67591" href="/z/d/graphic/66763.html" rel="external">
          picture 2A-E
         </a>
         ) [
         <a href="#rid2">
          2,9
         </a>
         ]. Eosinophils, plasma cells, and neutrophils also may be found. The classic lesion of "tubulitis" is found when inflammatory cells invade the tubular basement membrane (TBM).
        </p>
        <p>
         Some histologic features may suggest particular variants of AIN. As an example, granuloma formation is particularly characteristic of sarcoidosis, although it may be seen in any form of AIN [
         <a href="#rid91">
          91
         </a>
         ]. In some series, granuloma formation also suggests a greater likelihood of infection-induced AIN compared with AIN without granulomas. In a review of 40 biopsies of patients with granulomatous kidney disease (including 37 patients with interstitial nephritis, two with associated pauci-immune crescentic glomerulonephritis, and one with vasculitis), sarcoidosis was present in 20 patients (50 percent) and drug-induced and
         <em>
          Mycobacterium
         </em>
         infection present in seven (18 percent) and five (13 percent), respectively [
         <a href="#rid92">
          92
         </a>
         ]. However, in a number of other series, medication-induced interstitial nephritis was the leading cause of granulomatous interstitial nephritis, equaling or exceeding sarcoidosis in all.
        </p>
        <p>
         Infection is a more likely etiology in areas where infections associated with granulomatous disease are more common than in westernized countries [
         <a href="#rid45">
          45
         </a>
         ]. As described above, other infections that have been associated with granulomatous AIN include fungi (histoplasmosis, coccidioidomycosis), bacteria (
         <em>
          Brucella
         </em>
         ,
         <em>
          Chlamydia, Francisella
         </em>
         ), spirochetes (
         <em>
          Treponema
         </em>
         ), and parasites (
         <em>
          Leishmania
         </em>
         ,
         <em>
          Toxoplasma
         </em>
         ) [
         <a href="#rid44">
          44
         </a>
         ]. (See
         <a class="local">
          'Infections'
         </a>
         above.)
        </p>
        <p>
         Characteristic histologic features that suggest immunoglobulin G4 (IgG4)-related disease include the presence of TBM immune complex deposits and an increase in IgG4-positive plasma cells in the interstitium [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         Patients with interstitial nephritis related to lupus usually have concurrent glomerular lesions. (See
         <a class="medical medical_review" href="/z/d/html/3056.html" rel="external">
          "Lupus nephritis: Diagnosis and classification", section on 'Clinical features'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3056.html" rel="external">
          "Lupus nephritis: Diagnosis and classification", section on 'Histopathologic classification of LN'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3056.html" rel="external">
          "Lupus nephritis: Diagnosis and classification", section on 'Other forms of lupus kidney disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H451377245">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of AIN includes all other causes of AKI. The diagnostic approach to the patient with AKI from any cause is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7188.html" rel="external">
          "Diagnostic approach to adult patients with subacute kidney injury in an outpatient setting"
         </a>
         .)
        </p>
        <p>
         In general, the urinary findings will help distinguish AIN from other causes of AKI. The urinalysis, for example, typically shows granular and epithelial cell casts and free epithelial cells in acute tubular necrosis; red cell casts, as well as red and white cells in acute glomerulonephritis; and few, if any, abnormalities in prekidney disease and obstruction.
        </p>
        <p>
         Among patients with a predominance of white blood cells and white blood cell casts, renal atheroemboli should be considered, particularly among older patients [
         <a href="#rid93">
          93
         </a>
         ]. Similarly to AIN, renal atheroemboli may present with eosinophiluria, eosinophilia, and skin lesions. However, atheroemboli are more commonly associated with a reticular pattern (livedo reticularis) and digital infarcts, whereas AIN is associated with a characteristic rash that is diffuse and maculopapular. The history may also distinguish between AIN and renal atheroemboli. Many atheroemboli occur in the setting of atherosclerotic cardiovascular disease and are preceded by an endovascular procedure. (See
         <a class="medical medical_review" href="/z/d/html/7182.html" rel="external">
          "Clinical presentation, evaluation, and treatment of renal atheroemboli"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7182.html" rel="external">
          "Clinical presentation, evaluation, and treatment of renal atheroemboli", section on 'Risk factors'
         </a>
         .)
        </p>
        <p>
         Among patients who have a completely negative sediment, as in all patients with AKI of obscure origin, obstruction should be considered as part of the differential diagnosis. Imaging studies (usually an ultrasound) generally exclude the presence of obstruction, except in rare cases when the diagnosis of AKI is made within the first two to three days (see
         <a class="medical medical_review" href="/z/d/html/7174.html" rel="external">
          "Clinical manifestations and diagnosis of urinary tract obstruction (UTO) and hydronephrosis"
         </a>
         ). In all patients, imaging should be done prior to kidney biopsy.
        </p>
        <p>
         Some novel noninvasive biomarkers such as tumor necrosis factor-alpha, interleukin-9, and urine ratio of retinol-binding protein-to-creatinine may help distinguish AIN from other diagnosis [
         <a href="#rid94">
          94,95
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H451377368">
         <span class="h1">
          ESTABLISHING THE CAUSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once a diagnosis of AIN is made by biopsy, the underlying cause should be determined. As discussed above, the vast majority of cases of AIN are caused by a drug. A careful review of medications, including the timing of initiation in relation to the onset of acute kidney injury (AKI), may reveal the likely culprit agent.
        </p>
        <p>
         Less commonly, a drug is not identified or suspected. Among such patients, a histologic diagnosis of AIN should provoke a search for underlying infection and systemic disorders including systemic lupus erythematosus (SLE), sarcoidosis, Sjögren's disease, tubulointerstitial nephritis and uveitis (TINU) syndrome, IgG4 disease, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
        </p>
        <p>
         In some cases, histologic features may suggest the underlying disease that is associated with AIN. As an example, granulomas are more likely to be seen in patients with sarcoidosis than in other forms of AIN. Additionally, AIN related to SLE may be accompanied by characteristic glomerular lesions. Immunoglobulin G4 (IgG4)-related disease may be suggested by the presence of tubular basement membrane (TBM) immune complex deposits and an increase in immunoglobulin G4 (IgG4)-positive plasma cells in the interstitium [
         <a href="#rid55">
          55
         </a>
         ]. However, testing for IgG-4 specific plasma cells is not routinely performed at most centers.
        </p>
        <p>
         Such histologic features, although often suggestive, are not diagnostic, and, in general, the etiology of non-drug-related AIN must be established by means other than the kidney biopsy. Among patients who have AIN that is not believed to be related to a drug, we perform the following tests:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chest radiograph to evaluate for sarcoidosis, tuberculosis, and other infections. Among patients in whom the chest radiograph is nondiagnostic, a high-resolution chest computed tomography (CT) should be obtained to evaluate for sarcoidosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum levels of angiotensin-converting enzyme (ACE) and measurement of serum calcium and urinary calcium excretion to evaluate for sarcoidosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum QuantiFERON gold test or a purified protein derivative (PPD) to exclude tuberculosis, particularly in granulomatous AIN.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serologic tests, in select cases, to exclude histoplasmosis, coccidioidomycosis, toxoplasmosis, and Epstein-Barr virus (EBV). Urinary antigen test to exclude
         <em>
          Legionella
         </em>
         infection and urine culture to exclude leptospirosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ANCA to exclude ANCA-associated vasculitides.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antinuclear antibody (ANA) and double-stranded DNA (dsDNA) to exclude SLE.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         C3 and C4 to evaluate for SLE and IgG4-related disease and hypocomplementemic AIN. These tests, however, neither diagnose nor exclude these disorders.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anti-Ro/SSA, anti-La/SSb antibodies, C-reactive protein, and rheumatoid factor to exclude Sjögren's disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum protein electrophoresis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Slit lamp examination in patients with eye pain or redness to evaluate for tubulointerstitial nephritis and uveitis (TINU syndrome).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The diagnostic evaluation of a particular infection-related AIN should be guided by extrarenal clinical manifestations.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H535951049">
         <span class="h1">
          NSAID-INDUCED AIN AND NEPHROTIC SYNDROME
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonsteroidal antiinflammatory drugs (NSAIDs) may cause AIN with an interstitial infiltrate composed primarily of T lymphocytes, and with the nephrotic syndrome due to minimal change disease or membranous nephropathy [
         <a href="#rid79">
          79,96-98
         </a>
         ].
        </p>
        <p>
         This disorder is most likely to occur with
         <a class="drug drug_general" data-topicid="8440" href="/z/d/drug information/8440.html" rel="external">
          fenoprofen
         </a>
         but probably can be induced by any nonselective NSAID. There have also been case reports of selective cyclooxygenase (COX)-2 inhibitors also being associated with this pattern of injury [
         <a href="#rid21">
          21,99,100
         </a>
         ].
        </p>
        <p>
         How NSAIDs produce AIN and nephrotic syndrome are not known; it is possible that COX inhibition by the NSAID results in the preferential conversion of arachidonic acid to leukotrienes, which can then activate helper T cells.
        </p>
        <p>
         Affected patients typically present with hematuria, pyuria, white cell casts, proteinuria, and an acute rise in the plasma creatinine concentration. The full picture of an allergic reaction (fever, rash, eosinophilia, and eosinophiluria) is typically absent, but one or more of these findings may be present. Spontaneous recovery generally occurs within weeks to a few months after therapy is discontinued [
         <a href="#rid79">
          79,96
         </a>
         ]. All NSAIDs should be terminated in patients suspected of having NSAID-induced AIN. Since topically administered NSAIDs can be systemically absorbed, such therapy should also be terminated [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p>
         There is no definitive evidence that corticosteroid therapy is beneficial in this setting. However, a course of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         may be considered in patients whose kidney failure persists more than one to two weeks after the NSAID has been discontinued [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7233.html" rel="external">
          "Treatment of acute interstitial nephritis"
         </a>
         .)
        </p>
        <p>
         Such patients should avoid the subsequent administration of NSAIDs. Relapse may occur with rechallenge [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3508768908">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110752.html" rel="external">
          "Society guideline links: Acute kidney injury in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6894387">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/83997.html" rel="external">
          "Patient education: Acute interstitial nephritis (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Acute interstitial nephritis (AIN) is a kidney lesion that causes a decline in kidney function and is characterized by an inflammatory infiltrate in the kidney interstitium. Drugs, particularly antibiotics, are the most common cause of AIN. Other causes include autoimmune disorders, infections, sarcoidosis, and tubulointerstitial nephritis with uveitis (TINU) syndrome. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Etiology
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Drugs
         </strong>
         – Drugs that most commonly cause AIN are nonsteroidal antiinflammatory drugs (NSAIDs, including selective cyclooxygenase [COX]-2 inhibitors), penicillins and cephalosporins,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         , antimicrobial sulfonamides,
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         and other quinolones, diuretics,
         <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">
          cimetidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">
          allopurinol
         </a>
         , proton pump inhibitors (PPIs), 5-aminosalicylates (eg,
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         ), and checkpoint-inhibiting monoclonal antibodies. Many other drugs can occasionally cause AIN. (See
         <a class="local">
          'Drugs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Infections
         </strong>
         – Infections that have been associated with AIN include
         <em>
          Legionella
         </em>
         ,
         <em>
          Leptospira
         </em>
         , cytomegalovirus (CMV), and
         <em>
          Streptococcus
         </em>
         . Other, less commonly associated organisms include
         <em>
          Corynebacterium diphtheriae
         </em>
         , Epstein-Barr virus (EBV),
         <em>
          Yersinia
         </em>
         , and polyomavirus.
         <em>
          Mycobacterium
         </em>
         infection is associated with a granulomatous variant of AIN. (See
         <a class="local">
          'Infections'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Autoimmune disorders
         </strong>
         – Autoimmune disorders that have been associated with AIN include sarcoidosis, Sjögren's disease, systemic lupus erythematosus (SLE), and granulomatosis with polyangiitis. Less common causes of AIN are immunoglobulin G4 (IgG4)-related disease, anti-tubular basement membrane (TBM) antibodies, hypocomplementemic tubulointerstitial nephritis, and the TINU syndrome. (See
         <a class="local">
          'Associated with systemic disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – Patients with AIN present with nonspecific signs and symptoms associated with acute kidney injury (AKI). Signs and symptoms of an allergic-type reaction may be present, including rash, fever, and eosinophilia, although only 10 percent of patients have the full triad of rash, fever, and eosinophilia. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Laboratory findings
         </strong>
         – Patients generally present with a rise in the plasma creatinine concentration, which (if drug induced) is temporally related to administration of the offending drug. Urine sediment usually reveals white cells, red cells, and white cell casts. Urinary eosinophils may be present but lack the specificity and sensitivity to either exclude or diagnose AIN. Protein excretion is usually only mildly or moderately increased. (See
         <a class="local">
          'Laboratory and radiographic findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – AIN should be suspected in a patient who presents with an elevated serum creatinine and a urinalysis that shows white cells, white cell casts, and, in some cases, eosinophiluria. Drug-induced AIN should be suspected when the onset of characteristic laboratory findings are temporally related to the initiation of a new drug, particularly one that has been previously reported to cause AIN. A definitive diagnosis of AIN is made by kidney biopsy. Selected patients with suspected AIN will benefit from kidney biopsy. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Establishing the cause
         </strong>
         – Patients who have a histologic diagnosis of AIN and are not on a drug known to cause AIN should be evaluated for another underlying etiology. (See
         <a class="local">
          'Establishing the cause'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Rossert JA, Fischer EA. Acute interstitial nephritis. In: Comprehensive Clinical Nephrology, 2, Johnson RJ, Feehally J (Eds), Elsevier Limited, Philadelphia 2003. Vol 1, p.769.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neilson EG. Pathogenesis and therapy of interstitial nephritis. Kidney Int 1989; 35:1257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ten RM, Torres VE, Milliner DS, et al. Acute interstitial nephritis: immunologic and clinical aspects. Mayo Clin Proc 1988; 63:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michel DM, Kelly CJ. Acute interstitial nephritis. J Am Soc Nephrol 1998; 9:506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossert J. Drug-induced acute interstitial nephritis. Kidney Int 2001; 60:804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarz A, Krause PH, Kunzendorf U, et al. The outcome of acute interstitial nephritis: risk factors for the transition from acute to chronic interstitial nephritis. Clin Nephrol 2000; 54:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang CW, Wu MS, Pan MJ, et al. The Leptospira outer membrane protein LipL32 induces tubulointerstitial nephritis-mediated gene expression in mouse proximal tubule cells. J Am Soc Nephrol 2002; 13:2037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsai JD, Lee HC, Lin CC, et al. Epstein-Barr virus-associated acute renal failure: diagnosis, treatment, and follow-up. Pediatr Nephrol 2003; 18:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baker RJ, Pusey CD. The changing profile of acute tubulointerstitial nephritis. Nephrol Dial Transplant 2004; 19:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kodner CM, Kudrimoti A. Diagnosis and management of acute interstitial nephritis. Am Fam Physician 2003; 67:2527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Praga M, González E. Acute interstitial nephritis. Kidney Int 2010; 77:956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buysen JG, Houthoff HJ, Krediet RT, Arisz L. Acute interstitial nephritis: a clinical and morphological study in 27 patients. Nephrol Dial Transplant 1990; 5:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muriithi AK, Leung N, Valeri AM, et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. Am J Kidney Dis 2014; 64:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nolan CM, Abernathy RS. Nephropathy associated with methicillin therapy. Prevalence and determinants in patients with staphylococcal bacteremia. Arch Intern Med 1977; 137:997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galpin JE, Shinaberger JH, Stanley TM, et al. Acute interstitial nephritis due to methicillin. Am J Med 1978; 65:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nessi R, Bonoldi GL, Redaelli B, di Filippo G. Acute renal failure after rifampicin: a case report and survey of the literature. Nephron 1976; 16:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allon M, Lopez EJ, Min KW. Acute renal failure due to ciprofloxacin. Arch Intern Med 1990; 150:2187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo WK, Rolston KV, Rubenstein EB, Bodey GP. Ciprofloxacin-induced nephrotoxicity in patients with cancer. Arch Intern Med 1993; 153:1258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           World MJ, Stevens PE, Ashton MA, Rainford DJ. Mesalazine-associated interstitial nephritis. Nephrol Dial Transplant 1996; 11:614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torpey N, Barker T, Ross C. Drug-induced tubulo-interstitial nephritis secondary to proton pump inhibitors: experience from a single UK renal unit. Nephrol Dial Transplant 2004; 19:1441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esteve JB, Launay-Vacher V, Brocheriou I, et al. COX-2 inhibitors and acute interstitial nephritis: case report and review of the literature. Clin Nephrol 2005; 63:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoppes T, Prikis M, Segal A. Four cases of nafcillin-associated acute interstitial nephritis in one institution. Nat Clin Pract Nephrol 2007; 3:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang YC, Lin YF, Chao TK, et al. Acute interstitial nephritis with prominent eosinophil infiltration. Clin Nephrol 2009; 71:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaughan WJ, Sheth VR, Francos GC, et al. Ranitidine-induced acute interstitial nephritis with epithelial cell foot process fusion. Am J Kidney Dis 1993; 22:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neelakantappa K, Gallo GR, Lowenstein J. Ranitidine-associated interstitial nephritis and Fanconi syndrome. Am J Kidney Dis 1993; 22:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Praga M, Sevillano A, Auñón P, González E. Changes in the aetiology, clinical presentation and management of acute interstitial nephritis, an increasingly common cause of acute kidney injury. Nephrol Dial Transplant 2015; 30:1472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brewster UC, Perazella MA. Proton pump inhibitors and the kidney: critical review. Clin Nephrol 2007; 68:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leonard CE, Freeman CP, Newcomb CW, et al. Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiol Drug Saf 2012; 21:1155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blank ML, Parkin L, Paul C, Herbison P. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int 2014; 86:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schubert C, Bates WD, Moosa MR. Acute tubulointerstitial nephritis related to antituberculous drug therapy. Clin Nephrol 2010; 73:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambruzs JM, Walker PD, Larsen CP. The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. Clin J Am Soc Nephrol 2014; 9:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gisbert JP, González-Lama Y, Maté J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2007; 13:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waters AM, Zachos M, Herzenberg AM, et al. Tubulointerstitial nephritis as an extraintestinal manifestation of Crohn's disease. Nat Clin Pract Nephrol 2008; 4:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Airy M, Raghavan R, Truong LD, Eknoyan G. Tubulointerstitial nephritis and cancer chemotherapy: update on a neglected clinical entity. Nephrol Dial Transplant 2013; 28:2502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seethapathy H, Herrmann SM, Sise ME. Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management. Kidney Med 2021; 3:1074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 2016; 90:638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murakami N, Motwani S, Riella LV. Renal complications of immune checkpoint blockade. Curr Probl Cancer 2017; 41:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perazella MA, Sprangers B. AKI in Patients Receiving Immune Checkpoint Inhibitors. Clin J Am Soc Nephrol 2019; 14:1077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortazar FB, Kibbelaar ZA, Glezerman IG, et al. Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. J Am Soc Nephrol 2020; 31:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seethapathy H, Zhao S, Chute DF, et al. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. Clin J Am Soc Nephrol 2019; 14:1692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang JF, Peng YS, Tsai CC, et al. A possible rare cause of renal failure in streptococcal infection. Nephrol Dial Transplant 2011; 26:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellis D, Fried WA, Yunis EJ, Blau EB. Acute interstitial nephritis in children: a report of 13 cases and review of the literature. Pediatrics 1981; 67:862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dharmarajan TS, Yoo J, Russell RO, Boateng YA. Acute post streptococcal interstitial nephritis in an adult and review of the literature. Int Urol Nephrol 1999; 31:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agrawal V, Crisi GM, D'Agati VD, Freda BJ. Renal sarcoidosis presenting as acute kidney injury with granulomatous interstitial nephritis and vasculitis. Am J Kidney Dis 2012; 59:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bijol V, Mendez GP, Nosé V, Rennke HG. Granulomatous interstitial nephritis: a clinicopathologic study of 46 cases from a single institution. Int J Surg Pathol 2006; 14:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hung CC, Chang CT, Chen KH, et al. Upregulation of chemokine CXCL1/KC by leptospiral membrane lipoprotein preparation in renal tubule epithelial cells. Kidney Int 2006; 69:1814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farr RW. Leptospirosis. Clin Infect Dis 1995; 21:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baksh FK, Finkelstein SD, Swalsky PA, et al. Molecular genotyping of BK and JC viruses in human polyomavirus-associated interstitial nephritis after renal transplantation. Am J Kidney Dis 2001; 38:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parkhie SM, Fine DM, Lucas GM, Atta MG. Characteristics of patients with HIV and biopsy-proven acute interstitial nephritis. Clin J Am Soc Nephrol 2010; 5:798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaidan M, Lescure FX, Brochériou I, et al. Tubulointerstitial nephropathies in HIV-infected patients over the past 15 years: a clinico-pathological study. Clin J Am Soc Nephrol 2013; 8:930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng JH, Zaidan M, Jhaveri KD, Izzedine H. Acute tubulointerstitial nephritis and COVID-19. Clin Kidney J 2021; 14:2151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szajek K, Kajdi ME, Luyckx VA, et al. Granulomatous interstitial nephritis in a patient with SARS-CoV-2 infection. BMC Nephrol 2021; 22:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liew SK, Nair B, So B, et al. Acute interstitial nephritis following SARS-CoV-2 virus vaccination. Clin Nephrol 2022; 97:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012; 366:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raissian Y, Nasr SH, Larsen CP, et al. Diagnosis of IgG4-related tubulointerstitial nephritis. J Am Soc Nephrol 2011; 22:1343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaseemuddin M, Schwartz MM, Dunea G, Kraus MA. Idiopathic hypocomplementemic immune-complex-mediated tubulointerstitial nephritis. Nat Clin Pract Nephrol 2007; 3:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kambham N, Markowitz GS, Tanji N, et al. Idiopathic hypocomplementemic interstitial nephritis with extensive tubulointerstitial deposits. Am J Kidney Dis 2001; 37:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta A, Jothy S, Somerville P, Zaltzman JS. Hypocomplementaemic immune complex tubulointerstitial nephritis. NDT Plus 2010; 3:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uchiyama-Tanaka Y, Mori Y, Kimura T, et al. Acute tubulointerstitial nephritis associated with autoimmune-related pancreatitis. Am J Kidney Dis 2004; 43:e18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takeda S, Haratake J, Kasai T, et al. IgG4-associated idiopathic tubulointerstitial nephritis complicating autoimmune pancreatitis. Nephrol Dial Transplant 2004; 19:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saeki T, Saito A, Yamazaki H, et al. Tubulointerstitial nephritis associated with IgG4-related systemic disease. Clin Exp Nephrol 2007; 11:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saeki T, Nishi S, Ito T, et al. Renal lesions in IgG4-related systemic disease. Intern Med 2007; 46:1365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saeki T, Nishi S, Imai N, et al. Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis. Kidney Int 2010; 78:1016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fervenza FC, Downer G, Beck LH Jr, Sethi S. IgG4-related tubulointerstitial nephritis with membranous nephropathy. Am J Kidney Dis 2011; 58:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cornell LD. IgG4-related kidney disease. Curr Opin Nephrol Hypertens 2012; 21:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andres G, Brentjens J, Kohli R, et al. Histology of human tubulo-interstitial nephritis associated with antibodies to renal basement membranes. Kidney Int 1978; 13:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paueksakon P, Revelo M, Lee SM, et al. Acute renal failure in a 64-year-old white man. Am J Kidney Dis 2000; 36:669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clayman MD, Michaud L, Brentjens J, et al. Isolation of the target antigen of human anti-tubular basement membrane antibody-associated interstitial nephritis. J Clin Invest 1986; 77:1143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz A, Fish AJ, Santamaria P, et al. Role of antibodies to tubulointerstitial nephritis antigen in human anti-tubular basement membrane nephritis associated with membranous nephropathy. Am J Med 1992; 93:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muriithi AK, Leung N, Valeri AM, et al. Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly. Kidney Int 2015; 87:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takahashi N, Saeki T, Komatsuda A, et al. Tubulointerstitial Nephritis with IgM-Positive Plasma Cells. J Am Soc Nephrol 2017; 28:3688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larsen CP, Trivin-Avillach C, Coles P, et al. LDL Receptor-Related Protein 2 (Megalin) as a Target Antigen in Human Kidney Anti-Brush Border Antibody Disease. J Am Soc Nephrol 2018; 29:644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cameron JS. Allergic interstitial nephritis: clinical features and pathogenesis. Q J Med 1988; 66:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goicoechea M, Rivera F, López-Gómez JM, Spanish Registry of Glomerulonephritis. Increased prevalence of acute tubulointerstitial nephritis. Nephrol Dial Transplant 2013; 28:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haas M, Spargo BH, Wit EJ, Meehan SM. Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. Am J Kidney Dis 2000; 35:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baldwin DS, Levine BB, McCluskey RT, Gallo GR. Renal failure and interstitial nephritis due to penicillin and methicillin. N Engl J Med 1968; 279:1245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clarkson MR, Giblin L, O'Connell FP, et al. Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant 2004; 19:2778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           González E, Gutiérrez E, Galeano C, et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int 2008; 73:940.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984; 310:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nolan CR 3rd, Anger MS, Kelleher SP. Eosinophiluria--a new method of detection and definition of the clinical spectrum. N Engl J Med 1986; 315:1516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corwin HL, Korbet SM, Schwartz MM. Clinical correlates of eosinophiluria. Arch Intern Med 1985; 145:1097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muriithi AK, Nasr SH, Leung N. Utility of urine eosinophils in the diagnosis of acute interstitial nephritis. Clin J Am Soc Nephrol 2013; 8:1857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sigala JF, Biava CG, Hulter HN. Red blood cell casts in acute interstitial nephritis. Arch Intern Med 1978; 138:1419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neugarten J, Gallo GR, Baldwin DS. Rifampin-induced nephrotic syndrome and acute interstitial nephritis. Am J Nephrol 1983; 3:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Averbuch SD, Austin HA 3rd, Sherwin SA, et al. Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte a interferon therapy for mycosis fungoides. N Engl J Med 1984; 310:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saha H, Mustonen J, Helin H, Pasternack A. Limited value of the fractional excretion of sodium test in the diagnosis of acute renal failure. Nephrol Dial Transplant 1987; 2:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lins RL, Verpooten GA, De Clerck DS, De Broe ME. Urinary indices in acute interstitial nephritis. Clin Nephrol 1986; 26:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Capecchi R, Giannese D, Moriconi D, et al. Renal Involvement in IgG4-Related Disease: From Sunlight to Twilight. Front Med (Lausanne) 2021; 8:635706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fogazzi GB, Ferrari B, Garigali G, et al. Urinary sediment findings in acute interstitial nephritis. Am J Kidney Dis 2012; 60:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perazella MA. Diagnosing drug-induced AIN in the hospitalized patient: a challenge for the clinician. Clin Nephrol 2014; 81:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joss N, Morris S, Young B, Geddes C. Granulomatous interstitial nephritis. Clin J Am Soc Nephrol 2007; 2:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Javaud N, Belenfant X, Stirnemann J, et al. Renal granulomatoses: a retrospective study of 40 cases and review of the literature. Medicine (Baltimore) 2007; 86:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espejo B, Herrero JC, Torres A, et al. [Immunoallergic interstitial nephritis vs. cholesterol atheroembolism. Differentiating characteristics]. Nefrologia 2003; 23:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moledina DG, Wilson FP, Pober JS, et al. Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis. JCI Insight 2019; 4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isik B, Alexander MP, Manohar S, et al. Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events. Kidney Int Rep 2021; 6:1022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abraham PA, Keane WF. Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. Am J Nephrol 1984; 4:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warren GV, Korbet SM, Schwartz MM, Lewis EJ. Minimal change glomerulopathy associated with nonsteroidal antiinflammatory drugs. Am J Kidney Dis 1989; 13:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mérida E, Praga M. NSAIDs and Nephrotic Syndrome. Clin J Am Soc Nephrol 2019; 14:1280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alper AB Jr, Meleg-Smith S, Krane NK. Nephrotic syndrome and interstitial nephritis associated with celecoxib. Am J Kidney Dis 2002; 40:1086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albrecht B, Giebel S, McCarron M, Prasad B. Cyclooxygenase-2 inhibitor-induced acute interstitial nephritis. BMJ Case Rep 2017; 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrews PA, Sampson SA. Topical non-steroidal drugs are systemically absorbed and may cause renal disease. Nephrol Dial Transplant 1999; 14:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohammed EP, Stevens JM. Recurrence of Arthrotec-associated nephrotic syndrome with re-challenge. Clin Nephrol 2000; 53:483.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7234 Version 36.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Rossert JA, Fischer EA. Acute interstitial nephritis. In: Comprehensive Clinical Nephrology, 2, Johnson RJ, Feehally J (Eds), Elsevier Limited, Philadelphia 2003. Vol 1, p.769.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2770107" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Pathogenesis and therapy of interstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3045437" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Acute interstitial nephritis: immunologic and clinical aspects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9513915" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Acute interstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11473672" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Drug-induced acute interstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11020015" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The outcome of acute interstitial nephritis: risk factors for the transition from acute to chronic interstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12138134" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The Leptospira outer membrane protein LipL32 induces tubulointerstitial nephritis-mediated gene expression in mouse proximal tubule cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12750978" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Epstein-Barr virus-associated acute renal failure: diagnosis, treatment, and follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14671029" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The changing profile of acute tubulointerstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12825841" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Diagnosis and management of acute interstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20336051" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Acute interstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2113219" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Acute interstitial nephritis: a clinical and morphological study in 27 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24927897" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Biopsy-proven acute interstitial nephritis, 1993-2011: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/879956" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Nephropathy associated with methicillin therapy. Prevalence and determinants in patients with staphylococcal bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/707534" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Acute interstitial nephritis due to methicillin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1105220" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Acute renal failure after rifampicin: a case report and survey of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2222106" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Acute renal failure due to ciprofloxacin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8494478" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Ciprofloxacin-induced nephrotoxicity in patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8671848" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Mesalazine-associated interstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15004262" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Drug-induced tubulo-interstitial nephritis secondary to proton pump inhibitors: experience from a single UK renal unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15909599" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : COX-2 inhibitors and acute interstitial nephritis: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17653125" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Four cases of nafcillin-associated acute interstitial nephritis in one institution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19203513" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Acute interstitial nephritis with prominent eosinophil infiltration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8352263" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Ranitidine-induced acute interstitial nephritis with epithelial cell foot process fusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8352262" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Ranitidine-associated interstitial nephritis and Fanconi syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25324356" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Changes in the aetiology, clinical presentation and management of acute interstitial nephritis, an increasingly common cause of acute kidney injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17722704" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Proton pump inhibitors and the kidney: critical review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22887960" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24646856" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20497752" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Acute tubulointerstitial nephritis related to antituberculous drug therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24262508" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17243140" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18838984" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Tubulointerstitial nephritis as an extraintestinal manifestation of Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24009289" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Tubulointerstitial nephritis and cancer chemotherapy: update on a neglected clinical entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34939017" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27282937" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28189263" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Renal complications of immune checkpoint blockade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31048326" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : AKI in Patients Receiving Immune Checkpoint Inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31896554" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31672794" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20841492" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A possible rare cause of renal failure in streptococcal infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7015263" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Acute interstitial nephritis in children: a report of 13 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10481957" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Acute post streptococcal interstitial nephritis in an adult and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22177616" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Renal sarcoidosis presenting as acute kidney injury with granulomatous interstitial nephritis and vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16501836" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Granulomatous interstitial nephritis: a clinicopathologic study of 46 cases from a single institution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16625148" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Upregulation of chemokine CXCL1/KC by leptospiral membrane lipoprotein preparation in renal tubule epithelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7578715" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Leptospirosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11479162" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Molecular genotyping of BK and JC viruses in human polyomavirus-associated interstitial nephritis after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20338962" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Characteristics of patients with HIV and biopsy-proven acute interstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23430209" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Tubulointerstitial nephropathies in HIV-infected patients over the past 15 years: a clinico-pathological study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34603692" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Acute tubulointerstitial nephritis and COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33419393" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Granulomatous interstitial nephritis in a patient with SARS-CoV-2 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35113012" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Acute interstitial nephritis following SARS-CoV-2 virus vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22316447" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : IgG4-related disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21719792" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Diagnosis of IgG4-related tubulointerstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17183262" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Idiopathic hypocomplementemic immune-complex-mediated tubulointerstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11157382" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Idiopathic hypocomplementemic interstitial nephritis with extensive tubulointerstitial deposits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25949412" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Hypocomplementaemic immune complex tubulointerstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14981637" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Acute tubulointerstitial nephritis associated with autoimmune-related pancreatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14736977" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : IgG4-associated idiopathic tubulointerstitial nephritis complicating autoimmune pancreatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17593518" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Tubulointerstitial nephritis associated with IgG4-related systemic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17827834" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Renal lesions in IgG4-related systemic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20720530" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21705127" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : IgG4-related tubulointerstitial nephritis with membranous nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22487688" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : IgG4-related kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/362036" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Histology of human tubulo-interstitial nephritis associated with antibodies to renal basement membranes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10977803" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Acute renal failure in a 64-year-old white man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3514674" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Isolation of the target antigen of human anti-tubular basement membrane antibody-associated interstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1466368" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Role of antibodies to tubulointerstitial nephritis antigen in human anti-tubular basement membrane nephritis associated with membranous nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25185078" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28794148" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Tubulointerstitial Nephritis with IgM-Positive Plasma Cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29074737" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : LDL Receptor-Related Protein 2 (Megalin) as a Target Antigen in Human Kidney Anti-Brush Border Antibody Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3051085" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Allergic interstitial nephritis: clinical features and pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22759386" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Increased prevalence of acute tubulointerstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10692269" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4176988" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Renal failure and interstitial nephritis due to penicillin and methicillin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15340098" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Acute interstitial nephritis: clinical features and response to corticosteroid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18185501" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6363936" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Renal syndromes associated with nonsteroidal antiinflammatory drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2431314" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Eosinophiluria--a new method of detection and definition of the clinical spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4004436" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Clinical correlates of eosinophiluria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24052222" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Utility of urine eosinophils in the diagnosis of acute interstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/686935" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Red blood cell casts in acute interstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6837651" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Rifampin-induced nephrotic syndrome and acute interstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6689738" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte a interferon therapy for mycosis fungoides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3112654" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Limited value of the fractional excretion of sodium test in the diagnosis of acute renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3769228" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Urinary indices in acute interstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33869249" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Renal Involvement in IgG4-Related Disease: From Sunlight to Twilight.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22677261" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Urinary sediment findings in acute interstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24691017" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Diagnosing drug-induced AIN in the hospitalized patient: a challenge for the clinician.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17699417" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Granulomatous interstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17505256" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Renal granulomatoses: a retrospective study of 40 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12778876" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : [Immunoallergic interstitial nephritis vs. cholesterol atheroembolism. Differentiating characteristics].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31092735" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Urine TNF-αand IL-9 for clinical diagnosis of acute interstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33912752" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6731494" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2629709" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Minimal change glomerulopathy associated with nonsteroidal antiinflammatory drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31416889" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : NSAIDs and Nephrotic Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12407655" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Nephrotic syndrome and interstitial nephritis associated with celecoxib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28536229" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Cyclooxygenase-2 inhibitor-induced acute interstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10052505" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Topical non-steroidal drugs are systemically absorbed and may cause renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10879670" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Recurrence of Arthrotec-associated nephrotic syndrome with re-challenge.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
